# Penumbra Inc: financial statements, quarterly

PEN · NYSE · CIK 1321732 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pen.md) · [Financials](/companies/pen/financials.md) · [Filings](/companies/pen/filings.md) · [Insiders](/companies/pen/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pen/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [285](/filings/0001321732-24-000025.md) | [279](/filings/0001321732-25-000086.md) | [299](/filings/0001321732-25-000098.md) | [301](/filings/0001321732-25-000109.md) | [316 d](/filings/0001321732-26-000007.md) | [324](/filings/0001321732-26-000019.md) | [339](/filings/0001321732-26-000037.md) | [355](/filings/0001321732-26-000043.md) | [385 d](/filings/0001321732-26-000007.md) | [375](/filings/0001321732-26-000019.md) | [390](/filings/0001321732-26-000037.md) | [410](/filings/0001321732-26-000043.md) |
| Cost of revenue | $m | [97.7](/filings/0001321732-24-000025.md) | [97.5](/filings/0001321732-25-000086.md) | [137](/filings/0001321732-25-000098.md) | [101](/filings/0001321732-25-000109.md) | [105 d](/filings/0001321732-26-000007.md) | [108](/filings/0001321732-26-000019.md) | [115](/filings/0001321732-26-000037.md) | [114](/filings/0001321732-26-000043.md) | [123 d](/filings/0001321732-26-000007.md) | [121](/filings/0001321732-26-000019.md) | [125](/filings/0001321732-26-000037.md) | [130](/filings/0001321732-26-000043.md) |
| Gross profit | $m | [187](/filings/0001321732-24-000025.md) | [181](/filings/0001321732-25-000086.md) | [163](/filings/0001321732-25-000098.md) | [200](/filings/0001321732-25-000109.md) | [211 d](/filings/0001321732-26-000007.md) | [216](/filings/0001321732-26-000019.md) | [224](/filings/0001321732-26-000037.md) | [240](/filings/0001321732-26-000043.md) | [262 d](/filings/0001321732-26-000007.md) | [253](/filings/0001321732-26-000019.md) | [265](/filings/0001321732-26-000037.md) | [280](/filings/0001321732-26-000043.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [130 d](/filings/0001321732-26-000007.md) | [144](/filings/0001321732-25-000086.md) | [142](/filings/0001321732-25-000098.md) | [140](/filings/0001321732-25-000109.md) | [148 d](/filings/0001321732-26-000007.md) | [153](/filings/0001321732-26-000019.md) | [160](/filings/0001321732-26-000037.md) | [169](/filings/0001321732-26-000043.md) | [181 d](/filings/0001321732-26-000007.md) | [193](/filings/0001321732-26-000019.md) | [199](/filings/0001321732-26-000037.md) | [204](/filings/0001321732-26-000043.md) |
| Operating income | $m | [35.0 d](/filings/0001321732-26-000007.md) | [12.1](/filings/0001321732-25-000086.md) | [(81.0)](/filings/0001321732-25-000098.md) | [35.4](/filings/0001321732-25-000109.md) | [42.8 d](/filings/0001321732-26-000007.md) | [40.4](/filings/0001321732-26-000019.md) | [40.8](/filings/0001321732-26-000037.md) | [48.8](/filings/0001321732-26-000043.md) | [59.2 d](/filings/0001321732-26-000007.md) | [38.2](/filings/0001321732-26-000019.md) | [41.0](/filings/0001321732-26-000037.md) | [50.7](/filings/0001321732-26-000043.md) |
| Interest expense | $m | [0.4 d](/filings/0001321732-24-000025.md) | [0.4](/filings/0001321732-24-000060.md) | [0.3](/filings/0001321732-24-000087.md) | [0.3](/filings/0001321732-25-000109.md) | [0.3 d](/filings/0001321732-26-000007.md) | [0.3](/filings/0001321732-26-000019.md) | [0.3](/filings/0001321732-26-000037.md) | [0.3](/filings/0001321732-26-000043.md) | [0.3 d](/filings/0001321732-26-000007.md) | [0.3](/filings/0001321732-26-000019.md) | [0.3](/filings/0001321732-26-000037.md) | [0.3](/filings/0001321732-26-000043.md) |
| Income tax | $m | [(16.1)](/filings/0001321732-24-000025.md) | [3.6](/filings/0001321732-25-000086.md) | [(17.7)](/filings/0001321732-25-000098.md) | [10.3](/filings/0001321732-25-000109.md) | [10.7 d](/filings/0001321732-26-000007.md) | [4.6](/filings/0001321732-26-000019.md) | [0.0](/filings/0001321732-26-000037.md) | [6.5](/filings/0001321732-26-000043.md) | [16.3 d](/filings/0001321732-26-000007.md) | [9.1](/filings/0001321732-26-000019.md) | [11.4](/filings/0001321732-26-000037.md) | [14.0](/filings/0001321732-26-000043.md) |
| Net income | $m | [54.2](/filings/0001321732-24-000025.md) | [11.0](/filings/0001321732-25-000109.md) | [(60.2)](/filings/0001321732-25-000109.md) | [29.5](/filings/0001321732-25-000109.md) | [33.7 d](/filings/0001321732-26-000007.md) | [39.2](/filings/0001321732-26-000043.md) | [45.3](/filings/0001321732-26-000043.md) | [45.9](/filings/0001321732-26-000043.md) | [47.3 d](/filings/0001321732-26-000007.md) | [32.6](/filings/0001321732-26-000043.md) | [34.8](/filings/0001321732-26-000043.md) | [42.3](/filings/0001321732-26-000043.md) |
| Diluted EPS | $ per share | [1.38](/filings/0001321732-24-000025.md) | [0.28](/filings/0001321732-25-000086.md) | [(1.55)](/filings/0001321732-25-000098.md) | [0.75](/filings/0001321732-25-000109.md) | not reported | [1.00](/filings/0001321732-26-000019.md) | [1.15](/filings/0001321732-26-000037.md) | [1.17](/filings/0001321732-26-000043.md) | not reported | [0.82](/filings/0001321732-26-000019.md) | [0.88](/filings/0001321732-26-000037.md) | [1.07](/filings/0001321732-26-000043.md) |
| Basic EPS | $ per share | [1.40](/filings/0001321732-24-000025.md) | [0.28](/filings/0001321732-25-000086.md) | [(1.55)](/filings/0001321732-25-000098.md) | [0.76](/filings/0001321732-25-000109.md) | not reported | [1.02](/filings/0001321732-26-000019.md) | [1.17](/filings/0001321732-26-000037.md) | [1.17](/filings/0001321732-26-000043.md) | not reported | [0.83](/filings/0001321732-26-000019.md) | [0.88](/filings/0001321732-26-000037.md) | [1.07](/filings/0001321732-26-000043.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [167](/filings/0001321732-25-000012.md) | [223](/filings/0001321732-24-000060.md) | [288](/filings/0001321732-24-000087.md) | [280](/filings/0001321732-24-000118.md) | [324](/filings/0001321732-26-000007.md) | [376](/filings/0001321732-25-000086.md) | [422](/filings/0001321732-25-000098.md) | [321](/filings/0001321732-25-000109.md) | [187](/filings/0001321732-26-000043.md) | [241](/filings/0001321732-26-000019.md) | [205](/filings/0001321732-26-000037.md) | [254](/filings/0001321732-26-000043.md) |
| Current assets | $m | [915](/filings/0001321732-25-000012.md) | [935](/filings/0001321732-24-000060.md) | [944](/filings/0001321732-24-000087.md) | [892](/filings/0001321732-24-000118.md) | [951](/filings/0001321732-26-000007.md) | [1,000](/filings/0001321732-25-000086.md) | [1,065](/filings/0001321732-25-000098.md) | [1,142](/filings/0001321732-25-000109.md) | [1,217](/filings/0001321732-26-000043.md) | [1,275](/filings/0001321732-26-000019.md) | [1,344](/filings/0001321732-26-000037.md) | [1,377](/filings/0001321732-26-000043.md) |
| Total assets | $m | [1,556](/filings/0001321732-25-000012.md) | [1,580](/filings/0001321732-24-000060.md) | [1,535](/filings/0001321732-24-000087.md) | [1,479](/filings/0001321732-24-000118.md) | [1,533](/filings/0001321732-26-000007.md) | [1,593](/filings/0001321732-25-000086.md) | [1,675](/filings/0001321732-25-000098.md) | [1,744](/filings/0001321732-25-000109.md) | [1,827](/filings/0001321732-26-000043.md) | [1,898](/filings/0001321732-26-000019.md) | [1,975](/filings/0001321732-26-000037.md) | [2,025](/filings/0001321732-26-000043.md) |
| Current liabilities | $m | [151](/filings/0001321732-25-000012.md) | [153](/filings/0001321732-24-000060.md) | [151](/filings/0001321732-24-000087.md) | [153](/filings/0001321732-24-000118.md) | [158](/filings/0001321732-26-000007.md) | [159](/filings/0001321732-25-000086.md) | [158](/filings/0001321732-25-000098.md) | [170](/filings/0001321732-25-000109.md) | [183](/filings/0001321732-26-000043.md) | [212](/filings/0001321732-26-000019.md) | [234](/filings/0001321732-26-000037.md) | [234](/filings/0001321732-26-000043.md) |
| Total liabilities | $m | [377](/filings/0001321732-25-000012.md) | [376](/filings/0001321732-24-000060.md) | [373](/filings/0001321732-24-000087.md) | [375](/filings/0001321732-24-000118.md) | [382](/filings/0001321732-26-000007.md) | [380](/filings/0001321732-25-000086.md) | [381](/filings/0001321732-25-000098.md) | [386](/filings/0001321732-25-000109.md) | [399](/filings/0001321732-26-000043.md) | [425](/filings/0001321732-26-000019.md) | [444](/filings/0001321732-26-000037.md) | [442](/filings/0001321732-26-000043.md) |
| Shareholders' equity | $m | [1,179](/filings/0001321732-26-000007.md) | [1,204](/filings/0001321732-25-000109.md) | [1,161](/filings/0001321732-25-000109.md) | [1,104](/filings/0001321732-25-000109.md) | [1,151](/filings/0001321732-26-000043.md) | [1,213](/filings/0001321732-26-000043.md) | [1,294](/filings/0001321732-26-000043.md) | [1,359](/filings/0001321732-26-000043.md) | [1,428](/filings/0001321732-26-000043.md) | [1,474](/filings/0001321732-26-000043.md) | [1,531](/filings/0001321732-26-000043.md) | [1,584](/filings/0001321732-26-000043.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [36.3 d](/filings/0001321732-26-000007.md) | [38.3](/filings/0001321732-25-000086.md) | [22.6 d](/filings/0001321732-25-000098.md) | [56.5 d](/filings/0001321732-25-000109.md) | [51.1 d](/filings/0001321732-26-000007.md) | [49.0](/filings/0001321732-26-000019.md) | [44.9 d](/filings/0001321732-26-000037.md) | [58.3 d](/filings/0001321732-26-000043.md) | [86.5 d](/filings/0001321732-26-000007.md) | [87.0](/filings/0001321732-26-000019.md) | [46.1 d](/filings/0001321732-26-000037.md) | [41.5 d](/filings/0001321732-26-000043.md) |
| Capital expenditure | $m | [3.6 d](/filings/0001321732-26-000007.md) | [5.8](/filings/0001321732-25-000086.md) | [4.5 d](/filings/0001321732-25-000098.md) | [5.5 d](/filings/0001321732-25-000109.md) | [5.4 d](/filings/0001321732-26-000007.md) | [13.5](/filings/0001321732-26-000019.md) | [15.6 d](/filings/0001321732-26-000037.md) | [16.2 d](/filings/0001321732-26-000043.md) | [18.4 d](/filings/0001321732-26-000007.md) | [13.7](/filings/0001321732-26-000019.md) | [13.5 d](/filings/0001321732-26-000037.md) | [15.1 d](/filings/0001321732-26-000043.md) |
| Share repurchases | $m | [0.0 d](/filings/0001321732-26-000007.md) | not reported | not reported | not reported | [(0.0) d](/filings/0001321732-26-000007.md) | not reported | not reported | not reported | [0.0 d](/filings/0001321732-26-000007.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.2](/filings/0001321732-24-000087.md) | [39.2](/filings/0001321732-24-000118.md) | [39.3](/filings/0001321732-24-000025.md) | [39.4](/filings/0001321732-25-000086.md) | [38.8](/filings/0001321732-25-000098.md) | [39.2](/filings/0001321732-25-000109.md) | [39.2](/filings/0001321732-26-000019.md) | [39.2](/filings/0001321732-26-000037.md) | [39.3](/filings/0001321732-26-000043.md) | [39.5](/filings/0001321732-26-000019.md) | [39.6](/filings/0001321732-26-000037.md) | [39.6](/filings/0001321732-26-000043.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 39,414,385 at 2026-10-14, from the cover of the [10-Q filed 2026-10-29](/filings/0001321732-26-000043.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 19:10 ET. No prices; not investment advice.